Epidemiological trends across the country, we have reasons for optimism. With mondays announcement from the monitoring board for moderna candidate vaccine and showed 95 efficacy, we have two safe vaccines that could be authorized by the food and Drug Administration to be distributed within weeks. Operation warp speed has delivered a safe vaccine in a number of ways. And ensure there are no delays in vaccine production. Because of this work, by the end of december, we expect to have 40 million doses of these two Vaccines Available for distribution pending f. D. A. Distribution and going to our most vulnerable americans. We have been laying the groundwork in administration for months. There are four major caps to get the manufactured product to americans safely in order to save lives. Allocation, distribution, administration and ongoing monitoring and data work. We have led the groundwork for these and paid for the vaccines and worked to ensure that the Administration Costs will be cover
Every day. And waiting two or four more months, we count into the tens of thousands of more deaths. A harm to the population, that no vaccine ever would even approach in decades or centuries. So, we believe that these vaccines will have their safety and their efficacy very well documented to the point we are today. We really look forward to the reviews with the fda who are independently with its vaccine review board, potentially approve these vaccines and the cdc and acip as the secretary said, would recommend. Then we look forward to the next two vaccines that we hope will be giving us data on their efficacy, in weeks to come. Maybe in early january for one of them. And for the other, it could be in the next few weeks, if data from trials running outside of the u. S. , or maybe slightly later with trials in the u. S. Read out. Thank you very much. I will pass to the coleader of me with the operations. Mr. Secretary, dr. Solari, my coleader, thank you for this opportunity to talk about
The U.S. Congress quietly empowered the Food and Drug Administration (FDA) by approving a provision in the omnibus spending bill that would give the agency the ability to ban off-label uses of [.]